Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gizem Calibasi-Kocal has a total of 210 co-authors. Here are the top co-authors by number of shared publications:

  • Yasemin Basbinar

    Department of Translational Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey

    17 shared publications
  • Hulya Ellidokuz

    Department of Preventive Oncology, Institute of Oncology, Dokuz Eylul University, 35330 İzmir, Türkiye

    11 shared publications
  • Yasemin Basbinar

    Department of Translational Oncology, Institute of Oncology, Dokuz Eylül University, İzmir, Türkiye

    9 shared publications
  • Hulya Ellidokuz

    Department of Preventive Oncology, Institute of Oncology, Dokuz Eylul University

    7 shared publications
  • Yasemin Baskin

    Dokuz Eylul University, Institute of Oncology, Department of Basic Oncology, Personalized Medicine and Pharmacogenomics/Genomics Research Centre-BIFAGEM, Izmir, Turkey

    6 shared publications
  • Hasan Kurter

    Dokuz Eylul University, Institute of Health Sciences, Department of Oncology, Izmir, Türkiye

    4 shared publications

Latest Publications

  • Open Access

    Pocket-Surface Discrete Differential Geometry as a Leakage-Robust Feature Class for Protein–Ligand Binding Affinity Prediction

    by Mehmet Ali Balcı, Erbil Çetin, Gizem Calibasi-Kocal, Ömer Akgüller

    Protein–ligand binding affinity prediction underpins structure-based drug discovery, yet random partitions of public benchmarks overestimate generalisation due to protein-family and ligand leakage, and the marginal value of explicit pocket-geometry descriptors over atom-level graph neural networks remains unclear. We computed a 59-dimensional discrete differential geometry descriptor on the ligand-aware solvent-excluded surface of 3285 PDBBind v2020 complexes, combining curvature distributions, the leading sixteen Laplace–Beltrami eigenvalues and a ten-point heat-kernel signature, and evaluated it in gradient-boosted tree pipelines across progressively stricter split regimes and two leak-proof external benchmarks, together with four mechanistically distinct injection strategies in a SchNet-style graph neural network. The descriptor lifted Pearson correlations by 0.111 on cluster-disjoint testing, 0.258 on LP-PDBBind DataSAIL S2 and 0.365 on CASF-2016, while in isolation reaching 0.456 to 0.594 on external benchmarks, on a par with X-Score and AutoDock Vina (version 1.2). TreeSHAP attribution localised the dominant signal to the heat-kernel signature. The four graph neural network injection strategies produced no statistically significant lift, indicating that distance-based message passing on atomic coordinates already captures much of the geometric content. Pocket-surface discrete differential geometry, therefore, offers an interpretable, leakage-robust and lightweight feature class for early-stage virtual screening, and motivates hybrid mesh-to-atom architectures.

  • Open Access

    DDR2-COL11A1 Transcriptional Coupling as a Candidate Therapeutic Target in Colorectal Cancer: Integrative Transcriptomic and Deep Learning Validation

    by Yasemin Başbınar, Ömer Akgüller, Asım Leblebici, Gizem Çalıbaşı Koçal, Mehmet Ali Balcı, Zerrin Isik, Hülya Ellidokuz

    Extracellular matrix (ECM) remodeling is a hallmark of colorectal cancer progression, yet the transcriptional mechanisms coordinating collagen deposition and matrix metalloproteinase activation remain incompletely understood. We performed integrated computational analysis of 680 samples across normal mucosa, adenoma, and carcinoma stages to characterize discoidin domain receptor (DDR)-mediated transcriptional networks during tumorigenesis. Stage-stratified correlation analysis of fourteen pathway genes revealed profound divergence between DDR1 and DDR2; DDR1 correlations remained weak across all stages, while DDR2 correlations strengthened 2.59-fold from normal to carcinoma. DDR2-COL11A1 exhibited the most dramatic coupling intensification, increasing from R2=0.007 in normal tissue to R2=0.549 in carcinoma, accompanied by 1.99-fold COL11A1 upregulation. Remarkably, pathway activation occurred despite stable DDR2 expression, indicating enhanced transcriptional coupling efficiency rather than receptor upregulation as the primary mechanism. Deep neural network classification achieved 93.14% accuracy distinguishing disease stages, with SHAP analysis independently validating DDR2-COL11A1 as the most important gene interaction for cancer classification. These findings establish DDR2-specific transcriptional coupling as a functionally important mechanism in colorectal cancer progression and identify COL11A1 as a critical downstream target, suggesting novel therapeutic strategies targeting coupling efficiency rather than receptor abundance.

  • Open Access

    Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade

    by Gizem Calibasi-Kocal

    Chemoresistance remains a major challenge in non-small cell lung cancer, especially for cisplatin (DDP)-based therapies, which are a mainstay of treatment. In their study, Dai et al investigate how inflammatory cytokines within the tumor microenvironment contribute to DDP resistance. By analyzing tumor samples from 20 non-small cell lung cancer patients and two resistant cell lines (A549/ DDP and SK-MES-1/DDP), the authors show that increased levels of interleukin (IL)-6, IL-8, and tumor necrosis factor-α are linked to resistance. Logistic regression identifies IL-6 and IL-8 as key risk factors. Functional experiments using tocilizumab, an IL-6 receptor antagonist, demonstrate a reduction in DDP half maximum inhibitory concentration, higher apoptosis rates, and decreased migration and invasion in resistant cells. Although the study has certain limitations, such as the analysis of only five inflammatory cytokines in a small, non-stratified patient cohort; it demonstrates that targeting the IL-6 cytokine axis may help overcome DDP resistance. Overall, the study highlights the inflammatory component of the tumor microenvironment as a modifiable driver of chemoresistance and provide a rationale for integrating cytokine blockade into platinum-based chemotherapy regimens to enhance therapeutic response.


  • Open Access

    Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities

    by Adile Buse Andac-Aktas, Gizem Calibasi-Kocal

    Colorectal cancer (CRC) remains one of the most lethal malignancies worldwide, with outcomes shaped not only by genetic alterations but also by the complexity of the tumor microenvironment (TME). The TME encompasses stromal and endothelial cells, extracellular matrix components, gut microbiota, and a diverse array of immune cells that dynamically interact to influence tumor initiation, progression, and therapeutic response. This review delineates the immunological landscape of CRC, highlighting the dual functions of innate immune cells—including tumor-associated macrophages, natural killer cells, dendritic cells, neutrophils, and mast cells—and adaptive immune players such as cytotoxic T lymphocytes, helper T-cell subsets, and B/plasma cells. These cellular interactions contribute to the heterogeneity between immunologically “hot” microsatellite instability-high (MSI-H) tumors, which are highly responsive to immunotherapy, and “cold” microsatellite-stable (MSS) tumors, which remain resistant. Key mechanisms of immune evasion, such as cancer immunoediting, checkpoint signaling, and exosome-mediated communication, are examined alongside prognostic tools like the Immunoscore that serve as biomarkers of immune infiltration. Emerging immunotherapeutic strategies, including checkpoint blockade, macrophage reprogramming, natural killer cell agonists, and microbiome modulation, are discussed with emphasis on both their promise and limitations in CRC management. By integrating current insights into immune–tumor interactions, the review underscores opportunities for developing personalized, TME-targeted interventions to improve CRC outcomes.


  • Open Access

    Confounder-Adjusted Differentiation of Colorectal Cancer via Dynamic Propagation of Pathway Influence

    by Larissa Margareta Batrancea, Ömer Akgüller, Mehmet Ali Balcı, Gizem Çalıbaşı Koçal, Lucian Gaban

    Colorectal cancer (CRC) exhibits profound molecular heterogeneity between left-sided and right-sided tumors with distinct therapeutic responses that current static genomic analyses incompletely explain. We developed Dynamic Functional Influence Computation (DynaFIC), a computational framework modeling time-resolved signal propagation through biological networks to quantify functional influence beyond static expression levels. Using the GSE39582 dataset comprising 583 primary CRC samples, we performed confounder-adjusted differential expression analysis controlling for microsatellite instability status, BRAF mutations, Tumor Node Metastasis (TNM) stage, age, and sex, identifying 105 laterality-associated genes that underwent DynaFIC temporal network analysis. Right-sided tumors exhibited dramatically higher network connectivity density despite fewer nodes, creating distributed vulnerability patterns with HOXC6 as the dominant regulator, achieving 200-fold influence through network amplification. Left-sided tumors showed compartmentalized, hierarchical organization with PRAC1 as the primary regulator and predictable expression-influence scaling. Temporal clustering revealed distinct propagation kinetics: right-sided tumors demonstrated rapid signal saturation requiring early intervention, while left-sided tumors exhibited sustained propagation permitting sequential approaches. Stability Volatility Index analysis showed right-sided tumors maintain significantly higher systemic vulnerability. These findings establish anatomical location as a fundamental network organizational principle, suggesting that incorporating temporal dynamics into cancer analysis reveals therapeutically relevant differences for precision medicine applications in colorectal cancer.


  • Open Access

    Epigenetic potentiation of 5-fluorouracil by HDAC inhibitor quisinostat enhances antitumor effects in colorectal cancer

    by Gizem Calibasi-Kocal, Hasan Kurter, Eylem Doga Nartas, Ender Berat Ellidokuz, Yasemin Basbinar

    Histone deacetylase (HDAC) inhibitors have emerged as promising epigenetic therapeutics in cancer treatment; however, their clinical efficacy in solid tumors remains limited. Quisinostat is a potent pan-HDAC inhibitor with demonstrated anticancer activity in various malignancies. This study evaluates the therapeutic potential of Quisinostat, in combination with 5-fluorouracil (5-FU), in colorectal cancer (CRC) cell lines. The effects of Quisinostat and 5-FU, as monotherapies and in combination, were investigated in HCT-116 and HT-29 CRC cell lines. H3K27 acetylation levels were assessed by immunofluorescence to evaluate epigenetic modulation. Cell viability, IC50 shifts, and proliferation were measured using resazurin assays and Ki-67 staining. Apoptosis and mitochondrial membrane potential (ΔΨm) were analyzed via Hoechst 33342/PI dual staining and JC-1 assays. Migration and epithelial-mesenchymal transition (EMT) phenotypes were evaluated through wound healing assays and E-cadherin/N-cadherin immunostaining. Quisinostat significantly increased H3K27 acetylation and enhanced the cytotoxic effect of 5-FU by lowering its IC50 in both cell lines. The combination treatment markedly suppressed proliferation, as evidenced by reduced Ki-67 expression. Quisinostat in combination with 5-FU significantly enhanced ΔΨm loss and apoptotic cell death. Furthermore, the combination treatment inhibited cell migration and reversed the EMT phenotype by increasing E-cadherin and decreasing N-cadherin expression. Quisinostat enhances the antitumor efficacy of 5-FU in CRC cells by promoting histone acetylation, augmenting cytotoxic and apoptotic responses, and reversing EMT-associated migratory phenotypes. These findings support the potential of Quisinostat as an effective adjunct to 5-FU-based chemotherapy in CRC.


  • Open Access

    Impact of enzymatic isolation on the propagation efficiency of patient-derived colorectal cancer organoids

    by Gizem Calibasi-Kocal, Tolga Sever, Aras Emre Canda, Leman Evren Kadioglu, Halil Ates, Yasemin Basbinar, Ender Ellidokuz

    Cancer organoids are three-dimensional in vitro models that closely replicate the genetic, phenotypic, and heterogeneity characteristics of original tumors, making them valuable tools in cancer research. However, the lack of standardized protocols limits their broader application. This study evaluates the role of enzymatic isolation in generating patient-derived organoids (PDOs) from colorectal cancer tissues by comparing four enzymatic methods: TrypLE, Trypsin–EDTA (T/E), Collagenase, and Hyaluronidase. Colorectal cancer tissues were processed using these enzymes, and cell viability, dissociation efficiency, and isolation quality were assessed via Trypan Blue exclusion assay and 7-AAD staining with flow cytometry. Cancer stem cells marked by LGR5 and CD133 were quantified via flow cytometry, while organoid generation and growth were monitored over 11 days using confocal microscopy. TrypLE and T/E demonstrated superior preservation of cell viability but limited dissociation efficiency, yielding lower cell count per milligram of tissue. In contrast, Collagenase and Hyaluronidase demonstrated superior tissue dissociation, yielding higher total cell counts and the highest proportions of LGR5positive and CD133positive stem cell populations. Collagenase produced the highest organoid counts, while Hyaluronidase supported the largest organoid expansion, with both enzymes generating larger organoid surface areas and a greater number of organoids compared to TrypLE and T/E. These results highlight Collagenase and Hyaluronidase as optimal choices for PDO generation, providing a framework for optimizing dissociation protocols. This study underscores the critical influence of enzymatic dissociation methods on the establishment and reliability of colorectal cancer patient-derived organoids, providing a foundation for optimizing PDO protocols and advancing their translational application in precision oncology.


  • Open Access

    Picropodophyllin, an IGF‑1 receptor inhibitor, enhances oxaliplatin efficacy in chemoresistant colorectal cancer HCT116 cells by reducing metastatic potential

    by Nurcin Kayacik, Hasan Kurter, Tolga Sever, Yasemin Basbinar, Gizem Calibasi‑Kocal

    The insulin‑like growth factor receptor (IGF‑1R) axis drives cellular growth, survival and chemoresistance in colorectal cancer (CRC) by promoting proliferative signaling, anti‑apoptotic effects and epithelial‑mesenchymal transition (EMT). Targeting the IGF‑1R pathway is therefore a promising strategy, not only for overcoming drug resistance, but also for reducing migration and metastatic behavior related to EMT. The present study aimed to evaluate the potential of picropodophyllin (PPP), a selective IGF‑1R inhibitor, to enhance the effects of oxaliplatin (OX) in HCT116 and OX‑resistant HCT116‑R cells. Cell viability was evaluated using a resazurin‑based assay following 48‑h combination treatment with OX at its IC50 concentrations (HCT116 cells, 53 µM and HCT116‑R cells, 324 µM) and PPP (1 µM). Migration was assessed using wound healing assays, with images captured and analyzed at 0 and 48 h. Additionally, immunofluorescence staining was performed to assess E‑cadherin and vimentin expression, evaluating epithelial and mesenchymal characteristics. In HCT116‑R cells, the combination of OX (53 µM) and PPP significantly reduced cell viability by 0.65‑fold compared with OX alone (P=0.0286). Wound healing assays demonstrated that combining PPP with OX (53 and 324 µM) significantly decreased migration, with 0.34‑fold and 0.22‑fold reductions, respectively (P<0.05). Immunofluorescence staining revealed that this combination also significantly increased E‑cadherin expression, by 1.37‑ and 1.63‑fold, respectively (P<0.05), indicating the role of PPP in enhancing epithelial characteristics and reducing EMT‑related drug resistance. These findings highlight the potential for combining PPP with OX to enhance the cytotoxic and anti‑metastatic effects of OX in chemo‑resistant CRC cells, thus offering a promising strategy for overcoming drug resistance and improving patient outcomes in CRC treatment.

  • Open Access

    AI-Assisted Survival Prediction in Colorectal Cancer: A Clinical Decision Support Tool

    by Hüseyin Koray Mısırlıoğlu, Asım Leblebici, Gizem Çalıbaşı Koçal, Hülya Ellidokuz, Yasemin Başbınar

    Purpose: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Accurate survival prediction is crucial for advanced-stage patients to optimize treatment strategies and improve clinical outcomes. This study aimed to develop an artificial intelligence-assisted clinical decision support system (CDSS) for survival prediction in CRC patients using clinical and genomic data from the Cancer Genome Atlas Colon Adenocarcinoma Collection (TCGA-COAD) dataset. Methods: Machine learning algorithms, including C4.5 Decision Tree, Support Vector Machines (SVM), Random Forest, and Naive Bayes, were employed to create survival prediction models. Clinical parameters and genomic data from key pathways, such as glycolysis/gluconeogenesis and mTORC1, were integrated into the models. The models were evaluated based on accuracy and performance. Results: The Random Forest algorithm achieved the highest accuracy (82.3%) when only clinical parameters were used. When clinical data were combined with gene expression data, the model’s accuracy increased further. The resulting models were incorporated into a user-friendly web interface, SurvCOCA, for clinical use. Conclusions: This study demonstrates the potential of AI-based tools to improve prognosis predictions in CRC patients. Further research is needed, with larger datasets and additional machine learning algorithms, to enhance clinical decision-making and optimize treatment strategies.